AstraZeneca PLC (AZN)
After hours:
| Previous close | 77.04 |
| Open | 76.94 |
| Bid | 76.95 x 600 |
| Ask | 77.00 x 600 |
| Day's range | 76.87 - 77.53 |
| 52-week range | 60.47 - 77.94 |
| Volume | |
| Avg. volume | 5,619,365 |
| Market cap | 239.958B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | 37.92 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.45 (1.88%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
- Reuters
PRESS DIGEST-British Business - May 14
The following are the top stories on the business pages of British newspapers. - Anglo American rejected a raised takeover offer of 34 billion pounds ($42.67 billion) from BHP Group on Monday, saying the world's largest listed miner "continues to significantly undervalue" the company. - JPMorgan Chase has pledged a further 40 million pounds ($50.22 million) in philanthropic investments in the UK over five years in a sign of its increasing focus on Britain.
- The Telegraph
UK pharma giants pledge £430m investment in France after Macron charm offensive
Britain’s two biggest pharmaceutical companies have pledged £430m of investment in France after a charm offensive by Emmanuel Macron.
- Zacks
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
